CORRECTION article

Front. Pharmacol., 03 November 2022

Sec. Ethnopharmacology

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1074679

Corrigendum: A Chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial

  • 1. Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

  • 2. Beijing University of Chinese Medicine, Beijing, China

In the published article, Jianxun Ren was erroneously included. The corrected author list and correspondence information appear below. Additionally, the Author contributions section has been revised to reflect this amendment.

Yingying Wan1†, Jiaxi Yang2†, Tianyue Ma2, Wenqian Wang2, Haonan Wang1, Wenting Sun1, Wanting Ye2, Lin Yang1 and Qiuai Kou1*

Correspondence: Qiuai Kou,

Author Contributions: QK, YW, and JY contributed to the study design. YW drafted the manuscript, and prepared the additional files. JY was responsible for obtaining ethics approval. TM, WW, HW, WY, and WS devised and discussed the study design. LY analyzed the main components of the Chinese medicine. All authors have read and agreed with the final manuscript.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

rheumatoid arthritis, female, randomized controlled trial, double-blind, placebo, Chinese medicine, protocol

Citation

Wan Y, Yang J, Ma T, Wang W, Wang H, Sun W, Ye W, Yang L and Kou Q (2022) Corrigendum: A Chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial. Front. Pharmacol. 13:1074679. doi: 10.3389/fphar.2022.1074679

Received

19 October 2022

Accepted

20 October 2022

Published

03 November 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Qiuai Kou,

†These authors have contributed equally to this work and share first authorship

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics